Slovenia

Reimbursed Care Access

Slovenia maintains a restrictive legal regime for classic psychedelics (psilocybin, MDMA, DMT, mescaline, 2C-X, 5‑MeO‑DMT, ayahuasca, etc.), which are listed under national controlled‑substances regulations and have no routine medical reimbursement outside approved clinical research. Esketamine (Spravato) is authorised at the EU level and can be prescribed in Slovenia; reimbursement depends on placement on the national positive list administered by the Health Insurance Institute (ZZZS) and local hospital practice. Ketamine is an established anaesthetic and analgesic in routine clinical care (and is used off‑label for psychiatric indications), but off‑label psychiatric uses generally lack consistent public reimbursement and are typically delivered in private/ hospital settings or as self‑funded care unless the use is incorporated into an approved, reimbursed pathway.